A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2012

At a glance

  • Drugs Tofacitinib (Primary) ; Moxifloxacin
  • Indications Ankylosing spondylitis; Plaque psoriasis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top